Simultaneous quantification of twenty-eight components of Shenfu Injection in rat plasma by UHPLC-QQQ MS and its application to a pharmacokinetic study

Shen, Bingqing; Qu, Cheng; Li, Mi; Wang, Huiying; Yang, Hua

doi:10.1016/j.jpba.2021.114211

Cited by 7 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protopanaxatriol (PPT) ginsenosides such as ginsenoside Re (Figure 4), Rg1 (Figure 5) and Rg2 (Figure 6) can be rapidly excreted into bile when ginsenosides was given to rats (Cai et al, 2022). The elimination rate of protopanaxadiol ginsenosides such as ginsenoside Rb1 (Figure 7), Rd (Figure 8) and Rh2 (Figure 9) is slower than that of PPT ginsenosides (Li et al, 2015;Zhang et al, 2016;Shen et al, 2021). The pharmacokinetic properties of ginsenosides (ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rc (Figure 10)) and aconitine alkaloids (benzoylmesaconine (Figure 11), aconitine (Figure 12)) in SFI showed a linear relationship in the dose range of 2-8 mL/kg (Zhang et al, 2016;Li S. et al, 2022).…”

Section: Bioavailability and Metabolism Of Sfimentioning

confidence: 99%

Shenfu injection: a review of pharmacological effects on cardiovascular diseases

Xu,

Xie,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Shenfu injection (SFI), composed of ginseng and aconite, is a Chinese patent developed from the classic traditional prescription Shenfu Decoction created more than 700 years ago. SFI has been widely used in China for over 30 years for treating cardiovascular diseases. The main components in it include ginsenosides and aconitum alkaloids. In recent years, the role of SFI in the treatment of cardiovascular diseases has attracted much attention. The pharmacological effects and therapeutic applications of SFI in cardiovascular diseases are summarized here, highlighting pharmacological features and potential mechanisms developments, confirming that SFI can play a role in multiple ways and is a promising drug for treating cardiovascular diseases.

show abstract

Section: Bioavailability and Metabolism Of Sfimentioning

confidence: 99%

Shenfu injection: a review of pharmacological effects on cardiovascular diseases

Xu,

Xie,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…rough a search of the PubMed database, we found the latest research on UHPLC-QQQ MS (ultra-high performance liquid chromatography-triple quadrupole tandem mass spectrometry) for SFI [25]. Based on this UHPLC-QQQ MS research, we obtained 28 active ingredients of SFI, including 18 ginsenosides and 10 aconite alkaloids.…”

Section: Determination Of the Main Active Ingredients Of Sfi And Eval...mentioning

confidence: 99%

“…Parameters. Based on a recent UHPLC-QQQ MS study [25], a total of 28 active ingredients of SFI were obtained, including 18 ginsenosides and 10 aconite alkaloids. We used the HERB database to search for active ingredients in SFI to analyze their distribution in Chinese herbal medicines, and we can see that the distribution of active ingredients was specific.…”

Section: Main Active Ingredients Of Sfi and Eir Pharmacologicalmentioning

confidence: 99%

Therapeutic Mechanism and Key Active Ingredients of Shenfu Injection in Sepsis: A Network Pharmacology and Molecular Docking Approach

Yuan

Yang

Huang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

At present, although the early treatment of sepsis is advocated, the treatment effect of sepsis is unsatisfactory, and the mortality rate remains high. Shenfu injection (SFI) has been used to treat sepsis with good clinical efficacy. Based on network pharmacology, this study adopted a new research strategy to identify the potential therapeutic targets and key active ingredients of SFI for sepsis from the perspective of the pathophysiology of sepsis. This analysis identified 28 active ingredients of SFI based on UHPLC-QQQ MS, including 18 ginsenosides and 10 aconite alkaloids. 59 targets were associated with the glycocalyx and sepsis pathways. Based on the number of targets related to the pathophysiological process of sepsis, we identified songorine, ginsenoside Rf, ginsenoside Re, and karacoline as the key active ingredients of SFI for the treatment of sepsis. According to the cluster analysis of MCODE and the validation on the GEO dataset, LGALS3, BCHE, AKT1, and IL2 were identified as the core targets. This study further explored the therapeutic mechanism and the key active ingredients of SFI in sepsis and provided candidate compounds for drug development.

show abstract

“…et al, 2015 ; Li et al, 2017b ), and Shenfu injectable powder ( Zhang et al, 2008 ; Li Z. et al, 2015 ; Zhang et al, 2016 )] have been elucidated ( He et al, 2015 ; Chen et al, 2019 ; Wei et al, 2019 ). Currently, the pharmacokinetic studies of aconites were usually reported on Shenfu injection ( Zhang et al, 2008 ; Zhang et al, 2016 ; Shen et al, 2021 ). There is no other relevant study with simultaneous quantification of three types of aconitines for oral preparations containing Fuzi-ginseng herb pair ( Xu et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Compatibility of Fuzi and Ginseng Significantly Increase the Exposure of Aconitines

et al. 2022

View full text Add to dashboard Cite

The herb-pair ginseng-Fuzi (the root of Aconitum carmichaelii) is the material basis of Shenfu prescriptions and is popular in traditional Chinese medicine for the treatment of heart failure, and even shock with severe-stage of COVID-19. A narrow therapeutic window of Fuzi may cause significant regional loss of property and life in clinics. Therefore, systemic elucidation of active components is crucial to improve the safety dose window of Shenfu oral prescriptions. A high performance liquid chromatography-mass spectrometry method was developed for quantification of 10 aconitines in SD rat plasma within 9 min. The limit of detection and the limit of quantification were below 0.032 ng/ml and 0.095 ng/ml, respectively. Furthermore, a systemic comparison with their pharmacokinetic characteristics after oral administration of a safe dosage of 2 g/kg of Fuzi and ginseng-Fuzi decoction for 24 h was conducted. Eight representative diester, monoester, and non-ester aconitines and two new active components (i.e., songorine and indaconitine) were all adopted to elucidating the differences of the pharmacokinetic parameters in vivo. The compatibility of Fuzi and ginseng could significantly increase the in vivo exposure of active components. The terminal elimination half-life and the area under the concentration-time curve of mesaconitine, benzoylaconitine, benzoylmesaconitine, benzoylhypaconitine, and songorine were all increased significantly. The hypaconitine, benzoylmesaconitine, and songorine were regarded as the main active components in vivo, which gave an effective clue for the development of new Shenfu oral prescriptions.

show abstract

Simultaneous quantification of twenty-eight components of Shenfu Injection in rat plasma by UHPLC-QQQ MS and its application to a pharmacokinetic study

Cited by 7 publications

References 23 publications

Shenfu injection: a review of pharmacological effects on cardiovascular diseases

Shenfu injection: a review of pharmacological effects on cardiovascular diseases

Therapeutic Mechanism and Key Active Ingredients of Shenfu Injection in Sepsis: A Network Pharmacology and Molecular Docking Approach

Compatibility of Fuzi and Ginseng Significantly Increase the Exposure of Aconitines

Contact Info

Product

Resources

About